Zydus Lifesciences Limited has informed the Exchange about press release dated 07-Sep-2022 titled Zydus announces positive Phase 2 Proof-of-Concept of NLRP3 inhibitor, ZYIL1 in patients with Cryopyrin Associated Periodic Syndrome (CAPS)
Press Release Sep 07 2022
Filed with NSE · · 3 pages · English
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Aug 31 2022
- Press Release Aug 30 2022
- Press Release Aug 11 2022
- Press Release Aug 05 2022
- Press Release Aug 04 2022
Later from Zydus Lifesciences
- Press Release Sep 09 2022
- Press Release Sep 12 2022
- Press Release Sep 13 2022
- Press Release Sep 16 2022
- Press Release Sep 20 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences